Clinical Disease Patterns in a Regional Swiss Cohort of 34 Pyoderma Gangrenosum Patients

Background/Aim: Pyoderma gangrenosum (PG) is a rare, neutrophilic dermatosis often associated with an underlying disease, and clinical data or larger studies are rare. Methods: In this retrospective study, disease characteristics, clinical manifestations, and treatment response were evaluated in a Swiss cohort of PG patients. Results: In participating centers, 34 cases (21 females) of PG were analyzed based on clinical and histological presentation between 2002 and 2012. The mean age at diagnosis was 61.2 years; 50% of the patients experienced only 1 episode of PG. In 13 cases (out of 20), recurrences occurred during PG therapy; 64.1% showed only 1 lesion simultaneously. The predominant localization was the lower limb (67%). The lesions were disseminated in 26.6%. At the time of diagnosis or recurrence, the mean diameter was 37.6 mm and the mean ulcer size was 10.3 cm2. C-reactive protein (CRP) was elevated in 73.2%; leukocytosis was present in 58.9% and neutrophilia in 50.9%. At least 1 associated comorbidity was present in 85% (the most prominent being cardiovascular disease). The most often used systemic treatments were steroids (68.3%), cyclosporine A (31.7%), dapsone (31.7%), and infliximab (13.3%), and the most often used topicals were tacrolimus 0.1% (48.3%) and corticosteroids (35%). PG healed completely at discharge in 50.8%. The average time to diagnosis was 8 months, and the mean duration to healing was 7.1 months. Conclusion: PG is a difficult-to-diagnose skin disease. Here, markers for inflammation such as CRP, leukocytosis, and neutrophilia were elevated in 50-73% of the PG patients.

[1]  E. Berti,et al.  Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis) , 2017, The British journal of dermatology.

[2]  L. French,et al.  [Pyoderma gangrenosum and Sweet's syndrome : Cutaneous manifestations of autoinflammatory disorders]. , 2016, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[3]  A. Gottlieb,et al.  High‐dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum , 2016, Dermatologic therapy.

[4]  M. Augustin,et al.  Tricenter analysis of cofactors and comorbidity in patients with pyoderma gangrenosum , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[5]  E. Adışen,et al.  Pyoderma Gangrenosum , 2016, The international journal of lower extremity wounds.

[6]  P. Uysal,et al.  Inpatient Management of Pyoderma Gangrenosum: Treatments, Outcomes, and Clinical Implications. , 2016, Annals of plastic surgery.

[7]  L. French,et al.  Canakinumab in adults with steroid‐refractory pyoderma gangrenosum , 2015, The British journal of dermatology.

[8]  M. Gonçalo,et al.  Pyoderma gangrenosum: challenges and solutions , 2015, Clinical, cosmetic and investigational dermatology.

[9]  D. Fanoni,et al.  Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome , 2014, Clinical and experimental immunology.

[10]  U. Wollina,et al.  Pyoderma gangrenosum: pathogenetic oriented treatment approaches , 2014, Wiener Medizinische Wochenschrift.

[11]  D. Monteiro,et al.  Pyoderma gangrenosum after breast reduction: a rare complication. , 2013, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[12]  E. Guenova,et al.  Treatment of pyoderma gangrenosum with topical factor XIII. , 2013, European journal of dermatology : EJD.

[13]  J. Andrews,et al.  Systematic review: IBD‐associated pyoderma gangrenosum in the biologic era, the response to therapy , 2013, Alimentary pharmacology & therapeutics.

[14]  C. Rodríguez-Cerdeira,et al.  Clinical Application of Development of Nonantibiotic Macrolides That Correct Inflammation-Driven Immune Dysfunction in Inflammatory Skin Diseases , 2012, Mediators of inflammation.

[15]  S. Langan,et al.  Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. , 2012, The Journal of investigative dermatology.

[16]  E. Guenova,et al.  Case 1-2012: a man with persistent ulcers on the hands. , 2012, The New England journal of medicine.

[17]  R. Bosch,et al.  Pyoderma Gangrenosum: A Report of 15 Cases and Review of the Literature , 2012 .

[18]  R. Bhat Pyoderma gangrenosum: An update , 2012, Indian dermatology online journal.

[19]  A. Qureshi,et al.  Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients , 2011, The British journal of dermatology.

[20]  M. Schaller,et al.  Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. , 2011, Archives of dermatology.

[21]  D. Liew,et al.  Pyoderma gangrenosum requiring inpatient management: A report of 26 cases with follow up , 2011, The Australasian journal of dermatology.

[22]  R. Gamelli,et al.  Postoperative pyoderma gangrenosum after elective abdominoplasty: a case report and review of the literature. , 2010, Journal of burn care & research : official publication of the American Burn Association.

[23]  L. French,et al.  Martorell hypertensive ischemic leg ulcer: a model of ischemic subcutaneous arteriolosclerosis. , 2010, Archives of dermatology.

[24]  Maeve A McAleer,et al.  Infantile pyoderma gangrenosum. , 2008, Journal of the American Academy of Dermatology.

[25]  J. Callen,et al.  Pyoderma gangrenosum: an update. , 2007, Rheumatic diseases clinics of North America.

[26]  J. Reichrath,et al.  Pyoderma gangrenosum: Clinical presentation and outcome in 18 cases and review of the literature , 2007, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[27]  G. Dunnill,et al.  Diagnosis and treatment of pyoderma gangrenosum , 2006, BMJ : British Medical Journal.

[28]  M. Lebwohl,et al.  Treatment of Skin Disease: Comprehensive Therapeutic Strategies , 2005 .

[29]  J. Reichrath,et al.  Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. , 2005, Journal of the American Academy of Dermatology.

[30]  A. Morita,et al.  Topical Tacrolimus Therapy for Pyoderma Gangrenosum , 2005, The Journal of dermatology.

[31]  R. Weenig,et al.  Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria , 2004, International journal of dermatology.

[32]  D. Vidal,et al.  Review of 26 cases of classical pyoderma gangrenosum: clinical and therapeutic features , 2004, The Journal of dermatological treatment.

[33]  Robert A. Silvermann Treatment of Skin Disease: Comprehensive Therapeutoc Strategies , 2003 .

[34]  A. Fleischer,et al.  Pyoderma Gangrenosum A Comparison of Typical and Atypical Forms with an Emphasis on Time to Remission. Case Review of 86 Patients from 2 Institutions , 2000, Medicine.

[35]  P. Driesch,et al.  Pyoderma gangrenosum: a report of 44 cases with follow‐up , 1997, The British journal of dermatology.

[36]  W. Su,et al.  Pyoderma gangrenosum: classification and management. , 1996, Journal of the American Academy of Dermatology.

[37]  W. Bergfeld,et al.  Pyoderma gangrenosum: a review. , 1988, Journal of the American Academy of Dermatology.